Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA507 versus Wegovy in adults with obesity
CTR20250241Phase 3Completed
- Sponsor
- Chongqing Chen'an Biopharmaceutical
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, sponsored by Chongqing Chen'an Biopharmaceutical. Started Jan 2025; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on CTR20250241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250241.